November 01, 2017
1 min read

Three clinicians elected to ASH executive committee

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Stephanie Lee
Agnes Lee

ASH today announced the election of three new members to its executive committee.

Stephanie Lee, MD — member of Fred Hutchinson Cancer Research Center and professor at University of Washington — will serve a 1-year term as vice president, followed by successive terms as president-elect and president.

Lee — whose research interests include outcomes and health services research in hematologic malignancies and allogeneic hematopoietic cell transplantation — has been an ASH member for 22 years. She has held various leadership positions with the society, most recently serving as secretary.

Agnes Lee, MD , and Joseph Mikhael, MD, will serve 4-year terms as ASH councilors.

Joseph Mikhael
Kenneth C. Anderson

Agnes Lee is professor of medicine at University of British Columbia (UBC), director of the thrombosis program at Vancouver Coastal Health and UBC, and director of Vancouver General Hospital’s hematology research program. Her research interests include cancer-associated and catheter-related thrombosis, anticoagulants and research methodology. She has been an ASH member for 19 years.

Mikhael is professor of medicine at Mayo Clinic in Arizona, deputy director of Mayo Clinic Cancer Center and associate dean at Mayo Clinic School of Graduate Medical Education. His research interests include multiple myeloma and other plasma cell disorders, education and communication skills in medicine, and pharmaco-economics. He has been an ASH member for 17 years.

All three newly elected executive committee members will begin their terms after this year’s ASH Annual Meeting and Exposition, which will be held Dec. 9-12 in Atlanta.

“In this time of unprecedented scientific progress, ASH continues to play a leading role in ensuring that these research advances are translated to the bedside to improve the care of hematology patients,” ASH President Kenneth C. Anderson, MD, of Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, said in a society-issued press release. “It is exciting to have such a diverse and accomplished group of leaders helping to guide the society as we work with policymakers, educators, researchers, clinicians, patients and other stakeholders to shape the future of hematology and work toward our ultimate goal of conquering blood diseases worldwide.”